Jonathan Zalevsky, Chief R&D Officer at Nektar Therapeutics ($NKTR), made 10 open market sales of company shares over the past year, totaling $312,624. His latest sale occurred on February 18, 2026. These transactions rank 7,454th among 11,678 insiders in our database, well below the average sale value of $8.6 million across 6.4 transactions per insider. Zalevsky reported no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 18, 2026 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | S | Common Stock | 180 | $73.00 | 21,174.0000 | 18,946,559 | 0.84% | 0.00% |
| Jan. 20, 2026 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | S | Common Stock | 3867 | $35.67 | 21,354.0000 | 18,946,559 | 15.33% | 0.02% |
| Dec. 22, 2025 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | A | Stock Option | 25000 | $0.00 | 25,000.0000 | 18,946,559 | 9999.99% | 0.13% |
| Dec. 22, 2025 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | A | Common Stock | 6250 | $0.00 | 25,221.0000 | 18,946,559 | 32.95% | 0.03% |
| Nov. 25, 2025 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | S | Common Stock | 1157 | $54.28 | 18,971.0000 | 18,946,559 | 5.75% | 0.01% |
| Nov. 21, 2025 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | A | Stock Option | 4766 | $0.00 | 4,766.0000 | 18,946,559 | 9999.99% | 0.03% |
| Nov. 21, 2025 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | A | Common Stock | 2666 | $0.00 | 20,128.0000 | 18,946,559 | 15.27% | 0.01% |
| Sept. 4, 2025 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | S | Common Stock | 793 | $32.43 | 18,390.0000 | 205,661,000 | 4.13% | 0.00% |
| Sept. 4, 2025 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | S | Common Stock | 432 | $33.60 | 17,958.0000 | 205,661,000 | 2.35% | 0.00% |
| Sept. 4, 2025 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | S | Common Stock | 189 | $34.41 | 17,769.0000 | 205,661,000 | 1.05% | 0.00% |
| Sept. 4, 2025 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | S | Common Stock | 307 | $35.69 | 17,462.0000 | 205,661,000 | 1.73% | 0.00% |
| Sept. 2, 2025 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | S | Common Stock | 485 | $30.10 | 19,183.0000 | 205,661,000 | 2.47% | 0.00% |
| Aug. 19, 2025 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | S | Common Stock | 725 | $26.59 | 19,668.0000 | 205,661,000 | 3.56% | 0.00% |
| Aug. 19, 2025 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | A | Stock Option | 16666 | $0.00 | 16,666.0000 | 205,661,000 | 9999.99% | 0.01% |
| May 19, 2025 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | S | Common Stock | 10712 | $0.67 | 305,892.0000 | 205,661,000 | 3.38% | 0.01% |
| Feb. 19, 2025 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | S | Common Stock | 10300 | $1.01 | 316,604.0000 | 205,661,000 | 3.15% | 0.01% |
| Dec. 19, 2024 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | S | Common Stock | 51115 | $0.94 | 326,904.0000 | 13,949,851 | 13.52% | 0.37% |
| Dec. 13, 2024 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | A | Stock Option | 375000 | $0.00 | 375,000.0000 | 13,949,851 | 9999.99% | 2.69% |
| Dec. 13, 2024 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | A | Stock Option | 270000 | $0.00 | 270,000.0000 | 13,949,851 | 9999.99% | 1.94% |
| Dec. 13, 2024 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | A | Common Stock | 135000 | $0.00 | 378,019.0000 | 13,949,851 | 55.55% | 0.97% |
| Nov. 19, 2024 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | S | Common Stock | 7785 | $1.01 | 243,019.0000 | 13,949,851 | 3.10% | 0.06% |
| Aug. 19, 2024 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | S | Common Stock | 6866 | $1.28 | 250,804.0000 | 190,001,000 | 2.66% | 0.00% |
| May 17, 2024 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | S | Common Stock | 7355 | $1.75 | 257,670.0000 | 190,001,000 | 2.78% | 0.00% |
| Feb. 20, 2024 | NEKTAR THERAPEUTICS | $NKTR | Zalevsky Jonathan | Chief R&D Officer | S | Common Stock | 9014 | $0.68 | 265,025.0000 | 190,001,000 | 3.29% | 0.00% |